Bmc Cancer

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer Abstract Background: New, third-generation aromatase inhibitors (AIs) have proven comparable or superior to the anti-estrogen tamoxifen for treatment of estrogen receptor (ER) and/or progesterone receptor (PR) positive breast cancer. AIs suppress total body and intratumoral estrogen levels. It is unclear whether in situ carcinoma cell aromatization is the primary source of estrogen production for tumor growth and whether the aromatase expression is predictive of response to endocrine therapy. Due to methodological difficulties in the determination of the aromatase protein, COX-2, an enzyme involved in the synthesis of aromatase, has been suggested as a surrogate marker for aromatase expression.

[1]  B. Rasmussen,et al.  An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer , 2009, Acta oncologica.

[2]  A. Giordano,et al.  Leptin signaling in breast cancer: An overview , 2008, Journal of cellular biochemistry.

[3]  M. Ellis,et al.  Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial , 2008, Breast Cancer Research and Treatment.

[4]  M. Piccart,et al.  Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Aas,et al.  Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels , 2008, Clinical Cancer Research.

[6]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[7]  Chien-Cheng Chen,et al.  Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms. , 2008, Molecular endocrinology.

[8]  A. Wardley.  The need for advanced breast cancer treatment guidelines: results of an internet-based survey. , 2008, Breast.

[9]  K. Mokbel,et al.  The role of cyclooxygenase-2 in breast cancer: review , 2008, Breast Cancer Research and Treatment.

[10]  Takashi Suzuki,et al.  Intracrinology of estrogens and androgens in breast carcinoma , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[11]  W. Miller,et al.  Predicting response and resistance to endocrine therapy , 2008, Cancer.

[12]  R. Bast,et al.  American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. , 2007, Journal of oncology practice.

[13]  W. Jiang,et al.  Cyclooxygenase‐2 mRNA expression correlates with aromatase expression in human breast cancer , 2007, Journal of surgical oncology.

[14]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Y. Sugimoto,et al.  Aromatase and COX in breast cancer: Enzyme inhibitors and beyond , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  Takashi Suzuki,et al.  Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. , 2007, Cancer research.

[17]  L. Skoog,et al.  Expression of COX-2 and steroid converting enzymes in breast cancer. , 2006, Oncology reports.

[18]  B. Rasmussen,et al.  Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays , 2006, Journal of Clinical Pathology.

[19]  S. Piato,et al.  Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium , 2006, Breast Cancer Research and Treatment.

[20]  N. Bundred,et al.  Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence , 2006, British Journal of Cancer.

[21]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[22]  D. Edwards,et al.  The validation of new aromatase monoclonal antibodies for immunohistochemistry—A correlation with biochemical activities in 46 cases of breast cancer , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  P. Lønning,et al.  Aromatase Inhibition: Translation into a Successful Therapeutic Approach , 2005, Clinical Cancer Research.

[24]  B. Potter,et al.  Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  J. Geisler.  Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  G. Hampton,et al.  An integrated view of aromatase and its inhibition , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  D. Edwards,et al.  Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Mendelson,et al.  Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans , 2002, Trends in Endocrinology & Metabolism.

[31]  P. Lønning,et al.  Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Brueggemeier,et al.  Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[33]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[34]  M. A. Blankenstein,et al.  Aromatase and COX-2 expression in human breast cancers , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma , 2001, Cancer.

[36]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Lønning,et al.  Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  P. Lønning,et al.  A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[40]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[41]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[42]  J. Thijssen,et al.  Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. , 1997, Cancer research.

[43]  C. Mendelson,et al.  Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. , 1996, Endocrinology.

[44]  C. Mendelson,et al.  Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. , 1995, Molecular endocrinology.

[45]  A. Purohit,et al.  Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor , 1994, Molecular and Cellular Endocrinology.

[46]  Y. Ito,et al.  Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. , 1994, Endocrine reviews.

[47]  Shiuan Chen,et al.  Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. , 1992, The American journal of pathology.

[48]  W. Miller,et al.  The significance of steroid metabolism in human cancer , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[49]  M. Reed,et al.  in situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4‐hydroxyandrostenedione , 1989, International journal of cancer.

[50]  R. Santen,et al.  In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. , 1984, The Journal of clinical endocrinology and metabolism.

[51]  A. Forrest,et al.  Significance of aromatase activity in human breast cancer. , 1982, Cancer research.

[52]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[53]  E. Jensen.  Estrogen receptors in hormone-dependent breast cancers. , 1975, Cancer research.

[54]  N. Harada,et al.  Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblasts , 2004, Breast Cancer Research and Treatment.

[55]  W. Yue,et al.  Intratumoral aromatase model: The effects of letrozole (CGS 20267) , 2004, Breast Cancer Research and Treatment.

[56]  H. Sasano,et al.  Immunolocalization of aromatase in human breast disorders using different antibodies , 2004, Breast Cancer Research and Treatment.

[57]  M. Dowsett,et al.  Comparison of biochemical aromatase activity with aromatase immunhistochemistry in human breast carcinomas , 2004, Breast Cancer Research and Treatment.